These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38328494)

  • 21. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
    Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
    Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
    Kang N; Jeon K; Kim H; Kwon OJ; Huh HJ; Lee NY; Daley CL; Koh WJ; Jhun BW
    Chest; 2021 Aug; 160(2):436-445. PubMed ID: 33621600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease.
    Kim JY; Kim NY; Jung HW; Yim JJ; Kwak N
    BMC Pulm Med; 2022 Jul; 22(1):269. PubMed ID: 35836160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of
    Kwon YS; Koh WJ; Daley CL
    Tuberc Respir Dis (Seoul); 2019 Jan; 82(1):15-26. PubMed ID: 30574687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine.
    Field SK; Cowie RL
    Chest; 2003 Oct; 124(4):1482-6. PubMed ID: 14555583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
    Ye JJ; Wu TS; Chiang PC; Lee MH
    J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.
    Mehta RT
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1893-902. PubMed ID: 8843300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
    Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0052822. PubMed ID: 36326247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.
    Ito M; Koga Y; Hachisu Y; Murata K; Sunaga N; Maeno T; Hisada T
    Respir Investig; 2022 Sep; 60(5):613-624. PubMed ID: 35781424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease.
    Lee JK; Kim S; Chong YP; Lee HJ; Shim TS; Jo KW
    Chest; 2024 Mar; ():. PubMed ID: 38508335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion.
    Mingora CM; Garcia BA; Mange KC; Yuen DW; Ciesielska M; van Ingen J; Flume PA; Dorman SE
    BMC Infect Dis; 2022 Mar; 22(1):246. PubMed ID: 35279081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study.
    Hajikhani B; Nasiri MJ; Hosseini SS; Khalili F; Karimi-Yazdi M; Hematian A; Nojookambari NY; Goudarzi M; Dadashi M; Mirsaeidi M
    J Glob Antimicrob Resist; 2021 Sep; 26():188-193. PubMed ID: 34153525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV.
    Uthman MM; Uthman OA; Yahaya I
    Cochrane Database Syst Rev; 2013 Apr; (4):CD007191. PubMed ID: 23633339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-tuberculous mycobacteriosis. What has been coming out].
    Kajiki A
    Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
    Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
    Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.
    Koh WJ; Hong G; Kim SY; Jeong BH; Park HY; Jeon K; Kwon OJ; Lee SH; Kim CK; Shin SJ
    Antimicrob Agents Chemother; 2013 May; 57(5):2281-5. PubMed ID: 23478956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria.
    Pfaeffle HOI; Alameer RM; Marshall MH; Houpt ER; Albon DP; Heysell SK
    Pulm Pharmacol Ther; 2021 Oct; 70():102058. PubMed ID: 34293446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS.
    Cohn DL; Fisher EJ; Peng GT; Hodges JS; Chesnut J; Child CC; Franchino B; Gibert CL; El-Sadr W; Hafner R; Korvick J; Ropka M; Heifets L; Clotfelter J; Munroe D; Horsburgh CR
    Clin Infect Dis; 1999 Jul; 29(1):125-33. PubMed ID: 10433575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of severe
    Zweijpfenning SMH; Kops SEP; Boeree MJ; Kuipers S; van Ingen J; Hoefsloot W; Magis-Escurra C
    ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34820449
    [No Abstract]   [Full Text] [Related]  

  • 40. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
    Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
    J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.